Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1701-1720 of 2,120 trials

Multifocal Motor Neuropathy: Empasiprubart vs. IVIg

We are studying whether Empasiprubart can improve muscle strength and function in adults with Multifocal Motor Neuropathy compared to standard IVIg treatment.

Multifocal Motor Neuropathy>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Pancreatic and Bile Duct Cancer: 68Ga-FAPI-46 PET Imaging Study

We are testing a new imaging method to better visualize pancreatic and bile duct cancers. This study aims to see how accurately it detects cancer and monitors treatment response.

Cholangiocarcinoma (Bile Duct Cancer)Pancreatic Carcinoma (Pancreatic Cancer)>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Bleeding Treatment in Thrombocytopenic Patients: FORMAT Study

We are studying whether adding fibrinogen to platelet transfusions helps patients with low platelet counts after chemotherapy stop bleeding. This trial will evaluate the effectiveness and safety of this treatment approach.

Blood Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematology

Type 2 Diabetes: Personalized Treatment Study

We are exploring how different diabetes medications work for patients based on their insulin response. The goal is to find biomarkers that help tailor treatments for better management of type 2 diabetes.

Type 2 Diabetes1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyInternal Medicine

Rectal Cancer: REGorafenib and Nivolumab Treatment

We are studying a new treatment combining REGorafenib and Nivolumab with short-course radiotherapy for patients with intermediate-risk rectal cancer. The aim is to see if this approach improves treatment response and safety before surgery.

Locally-advanced Rectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Melanoma with Brain Metastases: Immunotherapy Study

We are studying the effects of immunotherapy in melanoma patients with brain metastases who are also receiving steroid treatment. Our goal is to see if this combination improves outcomes compared to standard care.

Malignant Melanoma of Skin1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Clofarabine for Advanced Urothelial Carcinoma

We are studying the safety and effectiveness of Clofarabine in patients with locally advanced or metastatic urothelial carcinoma. The trial aims to find the highest dose that can be tolerated while assessing how well the treatment works.

Bladder Cancer3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Activated T-Cells for Graft vs Host Disease After Stem Cell Transplant

We are testing a new treatment using activated regulatory T-cells in patients shortly after stem cell transplantation. The aim is to see if it can safely reduce the risk and severity of acute graft vs host disease.

LeukaemiaAcute graft versus host disease1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

RSV Hospitalization Prevention: Abrysvo® Vaccine Study

We are studying whether the Abrysvo® vaccine can help prevent hospitalizations from RSV in adults aged 18 and older, especially those 60 and above. This research aims to improve respiratory health outcomes in older adults.

RSV Infection6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Advanced Solid Tumors: BMS-986482 Study

We are investigating the safety and dosage of BMS-986482 alone or with other therapies for patients with advanced solid tumors. This study aims to understand how well it works in combination with existing treatments.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Nodal T Cell Lymphoma: Duvelisib vs. Gemcitabine or Bendamustine

We are studying whether duvelisib can improve outcomes for patients with relapsed or refractory nodal T cell lymphoma. This trial compares its effects to standard treatments like gemcitabine or bendamustine.

Refractory Adult T-cell LymphomaRelapsed/Refractory Nodal T Cell Lymphoma with TFH Phenotype>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Primary Sjögren's Disease: Efgartigimod Treatment Study

We are testing a new medication, efgartigimod, for adults with Primary Sjögren's Disease to see if it helps reduce disease activity and improve symptoms compared to a placebo.

Sjögren's Syndrome>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Gastroenteropancreatic and Thoracic Neuroendocrine Tumors: Cabozantinib and Lanreotide Study

We are studying the safety and effectiveness of a new combination treatment for patients with gastroenteropancreatic and thoracic neuroendocrine tumors. This trial aims to find out if this combination can improve treatment outcomes compared to current options.

Gastroenteropancreatic and Thoracic Neuroendocrine TumorEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesEndocrinologyOncology

Acromegaly: Debio 4126 Treatment Study

We are testing a new formulation of Debio 4126 in patients with acromegaly who have been treated with other medications. The study aims to see if it helps maintain normal hormone levels and evaluates its safety compared to a placebo.

Acromegaly1-2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementEndocrinology

Epstein-Barr Virus Diseases: Tabelecleucel Treatment

We are studying a new treatment called tabelecleucel for individuals with Epstein-Barr virus-associated diseases. The goal is to see if it can improve health outcomes compared to current options.

EBV-Related Lymphoproliferative Disorder>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyInfectious DiseasesOncology

Immune-Related Rheumatological Events in Cancer Patients

We are collecting data on how to better diagnose and manage joint and muscle issues caused by cancer treatments. This study involves multiple centers to improve care for patients receiving checkpoint inhibitors.

Cancer (all types)>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyRheumatology

Gastric Cancer: HLX22 Treatment Study

We are studying a new drug, HLX22, combined with standard treatments for patients with advanced gastric cancer. The goal is to see if it works better and is safe compared to existing treatment options.

Gastric Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementGastroenterologyOncology

Status Epilepticus Treatment in Elderly Patients

We are investigating a new treatment for established status epilepticus in older adults. This study aims to provide evidence on how effective this treatment is for this vulnerable population.

Status Epilepticus>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurology

Stroke Care: HOPE Study on Blood Pressure Management

We are comparing standard blood pressure management to a personalized approach after mechanical thrombectomy for acute ischemic stroke patients. The goal is to see which method better supports recovery and brain health.

Acute Ischemic Stroke>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Pain Medication Tapering for Persistent Spinal Pain

We are studying how different methods of reducing pain medication affect disability in patients with Persistent Spinal Pain Syndrome Type II after spinal cord stimulation. This research may help improve pain management strategies.

Persistent Spinal Pain Syndrome Type II1-2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurologyOrthopedics and Traumatology